We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: Pharmacokinetics
MedXY News
EnglishTag

Pharmacokinetics

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Optimizing Busulfan Precision Dosing: A Synthesis of Real-World Pharmacokinetics, Obesity, and Drug Interactions
Clinical UpdatesBusulfanDeferasirox

Optimizing Busulfan Precision Dosing: A Synthesis of Real-World Pharmacokinetics, Obesity, and Drug Interactions

By MedXY|May 12, 2026

This review synthesizes clinical evidence on busulfan pharmacokinetics, highlighting the critical role of TDM, the impact of body weight normalization, and significant drug interactions with deferasirox.

Precision Dosing of Secukinumab in Hidradenitis Suppurativa: Insights from the SUNSHINE and SUNRISE Pooled Pharmacokinetic Analysis
Clinical Updatesbiologicshidradenitis suppurativa
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story

Precision Dosing of Secukinumab in Hidradenitis Suppurativa: Insights from the SUNSHINE and SUNRISE Pooled Pharmacokinetic Analysis

By MedXY|Mar 5, 2026

This review synthesizes the 52-week pooled results from two Phase 3 trials, detailing the pharmacokinetics, safety, and biomarker responses of secukinumab in moderate-to-severe hidradenitis suppurativa.

Once-Weekly Insulin GZR4: A Potential Paradigm Shift in Basal Insulin Therapy for Type 2 Diabetes
Diabetes & Endocrinologyonce-weekly insulinPharmacokinetics

Once-Weekly Insulin GZR4: A Potential Paradigm Shift in Basal Insulin Therapy for Type 2 Diabetes

By MedXY|Feb 4, 2026

A Phase 1b trial demonstrates that the once-weekly insulin GZR4 is safe, well-tolerated, and effective in lowering FPG and HbA1c in patients with T2DM, potentially offering a more convenient alternative to daily basal insulin.

Precision Dosing in the ICU: Extended Infusions of Meropenem and Piperacillin Optimize Therapy During Renal Replacement
Critical Careantimicrobial stewardshipcritical care

Precision Dosing in the ICU: Extended Infusions of Meropenem and Piperacillin Optimize Therapy During Renal Replacement

By MedXY|Dec 28, 2025

A large-scale multinational study reveals that meropenem and piperacillin dosing during renal replacement therapy must be tailored to RRT intensity and urine output, with extended infusions significantly improving therapeutic target attainm

Once‑Daily Dolutegravir/Lamivudine Fixed‑Dose Tablets Achieve Robust Pediatric Exposures and Reassuring Safety in the D3/PENTA 21 PK Sub‑Study
HIV/AIDSHIVPediatrics

Once‑Daily Dolutegravir/Lamivudine Fixed‑Dose Tablets Achieve Robust Pediatric Exposures and Reassuring Safety in the D3/PENTA 21 PK Sub‑Study

By MedXY|Nov 13, 2025

A nested PK and safety sub‑study of D3/PENTA 21 shows once‑daily DTG/3TC dispersible and film‑coated fixed‑dose tablets deliver adequate drug exposures across WHO weight bands in children 2–<15 years, with no drug‑related discontinuation

Dolutegravir from Birth: PETITE‑DTG Shows Safe, Targeted Neonatal Dosing for Term Newborns
HIV/AIDSdolutegravirHIV

Dolutegravir from Birth: PETITE‑DTG Shows Safe, Targeted Neonatal Dosing for Term Newborns

By MedXY|Nov 12, 2025

First randomized neonatal PK/safety data show 5 mg dolutegravir (dispersible tablet or oral film) every 48 hours for two weeks, then daily to day 28, achieves target troughs with acceptable safety in term infants born to mothers on dolutegr

Optimizing Pyrazinamide Dosing in Drug-Susceptible Pulmonary Tuberculosis: Insights from a Large Phase 3 Trial
Clinical Updatesdose optimizationPharmacokinetics

Optimizing Pyrazinamide Dosing in Drug-Susceptible Pulmonary Tuberculosis: Insights from a Large Phase 3 Trial

By MedXY|Oct 8, 2025

A comprehensive analysis from the TBTC Study 31/ACTG A5349 reveals that flat dosing of pyrazinamide at 1,000 mg daily optimizes efficacy and safety, challenging current weight-banded dosing strategies for drug-susceptible tuberculosis.

Amycretin: A Promising First-in-Class Dual GLP-1 and Amylin Receptor Agonist for Overweight and Obesity
Clinical UpdatesamycretinGLP-1 receptor agonist

Amycretin: A Promising First-in-Class Dual GLP-1 and Amylin Receptor Agonist for Overweight and Obesity

By MedXY|Oct 8, 2025

Amycretin, a novel dual GLP-1 and amylin receptor agonist, demonstrated safety, tolerability, and dose-proportional pharmacokinetics in adults with overweight or obesity, supporting further trials on its weight loss efficacy.

Dihydroberberine: Enhanced Absorption and Emerging Therapeutic Potential Based on Recent Clinical and Mechanistic Insights
Clinical UpdatesBerberinedihydroberberine

Dihydroberberine: Enhanced Absorption and Emerging Therapeutic Potential Based on Recent Clinical and Mechanistic Insights

By MedXY|Oct 4, 2025

Dihydroberberine demonstrates superior absorption compared to berberine, suggesting enhanced pharmacological properties. Recent studies highlight its potential in metabolic and inflammatory diseases, warranting further clinical exploration.

Recent Advances in Dihydroberberine Research: Pharmacokinetics, Mechanisms, and Clinical Potential
Clinical UpdatesBerberinedihydroberberine

Recent Advances in Dihydroberberine Research: Pharmacokinetics, Mechanisms, and Clinical Potential

By MedXY|Oct 4, 2025

This review synthesizes the latest 5-year evidence on dihydroberberine, highlighting improved bioavailability over berberine, mechanistic insights from metabolic and network pharmacology studies, and its promising clinical applications in m

Long-Acting Oral Weekly Risperidone (LYN-005): Translating Pharmacokinetic Equivalence to Clinical Opportunity in Schizophrenia
Clinical UpdatesPharmacokineticsschizophrenia

Long-Acting Oral Weekly Risperidone (LYN-005): Translating Pharmacokinetic Equivalence to Clinical Opportunity in Schizophrenia

By MedXY|Oct 1, 2025

Weekly LYN-005 demonstrated pharmacokinetic equivalence to daily risperidone, sustained therapeutic levels, and manageable safety in clinically stable patients, offering a novel option to address non-adherence in schizophrenia.

Why Do Some Medicines Require a ‘Loading Dose’? The Science Behind the First Double Dose
Internal MedicineAntibioticsPharmacokinetics

Why Do Some Medicines Require a ‘Loading Dose’? The Science Behind the First Double Dose

By MedXY|Dec 25, 2025

Exploring why certain medications start with a larger first dose, the clinical evidence, common misconceptions, and practical guidelines for safe use.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities